肺鱗狀細胞癌和肺腺癌中Cbl-b的表達及比較

2018年1月，中國醫科大學**醫院腫瘤內科；中國醫科大學**醫院；遼寧省抗癌藥物與生物治療重點實驗室；美國北卡羅來納州達勒姆；杜克大學醫學院醫學部；美國北卡羅來納州達勒姆；杜克大學醫學中心；杜克癌癥研究所；鄭州大學附屬腫瘤醫院中心實驗室；河南省腫瘤醫院；鄭州大學附屬腫瘤醫院；河南鄭州腫瘤醫院內科；鄭州大學附屬腫瘤醫院；河南鄭州腫瘤醫院分子病理科(Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, P.R. China；Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province,The First Hospital of China Medical University, Shenyang, Liaoning, P.R. China；Department of Medicine, Duke University School of Medicine, Durham, NC, U.S.A.；Duke Cancer Institute, Duke University Medical Center, Durham, NC, U.S.A.；Central Laboratory, Affiliated Cancer Hospital of Zhengzhou University,   Henan Cancer Hospital, Zhengzhou, Henan, P.R. China；Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, P.R. China；Department of Molecular Pathology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, P.R. China) Peng Li老師研究團隊在《Medical Science》上發表論文：

“Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma”

“肺鱗狀細胞癌和肺腺癌中Cbl-b的表達及比較”

Abstract：

BACKGROUND Non-small cell lung carcinoma (NSCLC) mainly includes lung squamous cell carcinoma and adenocarcinoma. This study aimed to investigate the difference between the expression of Cbl-b in lung squamous cell carcinoma and adenocarcinoma. MATERIAL AND METHODS The clinical features and survival data of NSCLC patients and Cbl-b mRNA (FPKM) were obtained from the TCGA database. Then, lung squamous cell carcinoma and adenocarcinoma cell lines were transfected with lentivirus-mediated RNA interference vector to knockdown the expression of Cbl-b. Next, a Transwell assay was performed to study the effect of Cbl-b shRNA on migration and invasion of lung squamous cell carcinoma and adenocarcinoma cells. Finally, Western blot analysis was performed to measure the expressions of PI3K, p-PI3K, AKT, p-AKT, ERK1/2, p-ERK1/2, GSK3β, p-GSK3β, mTOR, and p-mTOR protein in lung adenocarcinoma and squamous cell carcinoma cells. RESULTS The correlation of Cbl-b expression and OS was different between NSCLC adenocarcinoma and squamous carcinoma. After transfection, the expression of Cbl-b was inhibited in A549, H1975, and SW900 cells. Cbl-b shRNA promoted the migration and invasion of lung adenocarcinoma A549 and H1975 cells, but it inhibited the invasion of lung squamous cell carcinoma SW900 cells. In addition, Cbl-b regulated the expression of PI3K and ERK1/2-GSK3β pathway proteins in A549 and SW900 cells. CONCLUSIONS The OS of Cbl-b mRNA low expression in lung adenocarcinoma and squamous cell carcinoma was different. The difference in signal pathways may be one of the reasons for the difference in the correlation between Cbl-b expression and the survival rate of these 2 pathological types of lung cancer.

摘要：

背景：非小細胞肺癌主要包括肺鱗狀細胞癌和肺腺癌。本研究旨在探討肺鱗狀細胞癌和肺腺癌中cl -b表達的差異。材料與方法從TCGA數據庫獲取非小細胞肺癌患者的臨床特征和生存數據以及clc -b mRNA (FPKM)。然后，用慢病毒介導的RNA干擾載體轉染肺鱗狀細胞癌和腺癌細胞株，敲低Cbl-b的表達。接下來，科研人員通過Transwell實驗研究了cb -b shRNA對肺鱗癌和腺癌細胞遷移和侵襲的影響。最后，采用Western blot檢測肺腺癌和鱗癌細胞中PI3K、p-PI3K、AKT、p-AKT、ERK1/2、p-ERK1/2、GSK3β、p-GSK3β、mTOR和p-mTOR蛋白的表達。結果在非小細胞肺癌腺癌和鱗癌中，clc -b表達與OS的相關性存在差異。轉染后，Cbl-b在A549、H1975和SW900細胞中的表達受到抑制。Cbl-b shRNA促進肺腺癌A549和H1975細胞的遷移和侵襲，抑制肺鱗狀細胞癌SW900細胞的侵襲。此外，Cbl-b還可調控A549和SW900細胞中PI3K和ERK1/2-GSK3β通路蛋白的表達。結論肺腺癌和鱗癌組織中低表達的Cbl-b mRNA的OS不同。信號通路的差異可能是導致這兩種病理類型肺癌的clc -b表達與生存率相關性差異的原因之一。

該論文中肺腺癌細胞系(A549, H1975, H1299)和肺鱗狀細胞癌細胞系(SW900)的體外培養是使用Ausbian特級胎牛血清完成的。欲了解或購買Ausbian特級胎牛血清可以聯系北京締一生物400-166-8600.